Facebook
X
LinkedIn
ForwardTheranostics - 2026 APP Summit
This course provides an overview of the rapidly evolving field of theranostics, highlighting how targeted radiopharmaceuticals are used for both diagnosing and treating cancer at the cellular level. Participants will learn about current FDA‑approved therapies, radiation safety principles, and emerging clinical trial developments shaping the future of personalized oncology care.
Target Audience
This activity is intended for physician assistants, nurse practitioners, nurse midwives, and nurse anesthetists.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the principles, evolution, and clinical significance of theranostics in modern medical practice.
- Differentiate the indications, mechanisms of action, administration processes, radiation‑safety considerations, and patient‑education needs for the three FDA‑approved medications used in the treatment of Prostate Cancer and Neuroendocrine Tumors (NET).
- Apply key programmatic considerations—including workflow planning, radiation‑safety procedures, and integration of clinical trial protocols—when implementing or managing a clinical theranostics program..
Presenter: Jacqueline Ligorski CRNP, MSN, FNP-BC, AGACNP-BC, AOCNP - Hematology Oncology Specialist, UPMC
Conflict of Interest Disclosure:
No members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
DISCLAIMER STATEMENT
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Assistant (AAPA)
The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
Nursing (CNE)
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour.
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
Available Credit
- 0.50 AAPA Category I CME
- 0.50 ANCCUPMC Provider Unit is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation
- 0.50 Attendance